Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
20.09
-0.57 (-2.76%)
Aug 11, 2025, 2:11 PM - Market open
Inozyme Pharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover Inozyme Pharma stock have a consensus rating of "Buy" and an average price target of $50, which forecasts a 148.88% increase in the stock price over the next year. The lowest target is $31 and the highest is $70.
Price Target: $50 (+148.88%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 16, 2025.
Analyst Ratings
The average analyst rating for Inozyme Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +148.88% | Jun 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +148.88% | Jun 13, 2025 |
| UBS | UBS | Strong Buy Maintains $44 → $38 | Strong Buy | Maintains | $44 → $38 | +89.15% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $36 → $31 | Hold | Maintains | $36 → $31 | +54.31% | May 9, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $46 → $43 | Buy | Maintains | $46 → $43 | +114.04% | May 9, 2025 |
Financial Forecast
Revenue This Year
3.65M
from 7.02M
Decreased by -48.08%
Revenue Next Year
2.93M
from 3.65M
Decreased by -19.56%
EPS This Year
-3.52
from -2.45
EPS Next Year
-4.10
from -3.52
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.2M | 12.6M | 104.1M | ||
| Avg | 3.6M | 2.9M | 35.8M | ||
| Low | 681,100 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.1% | 245.7% | 3,451.8% | ||
| Avg | -48.1% | -19.6% | 1,121.7% | ||
| Low | -90.3% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.23 | -3.36 | -2.77 | ||
| Avg | -3.52 | -4.10 | -3.90 | ||
| Low | -3.84 | -4.71 | -5.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.